Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription factor BTF3 homolog 4 (*BTF3L4*) is a protein coding gene in humans (UniProtKB Q96K17) that encodes a member of the NAC-beta family. BTF3L4 acts as a putative transcription factor involved in gene regulation, particularly via modulating transcriptional processes. It may have functional overlap or paralogous relationships with BTF3. Recent studies suggest a possible role in cancer, as it can enhance malignant phenotypes and influence the immune microenvironment in glioma, but direct targeting with drugs has not been reported[2][5][8][10]. BTF3L4 is broadly expressed with no specific tissue restriction and has standard features of transcription factor proteins such as DNA binding domains.\n\nIf more specific mechanistic or pharmacological data become available in future publications or clinical datasets, the above characterizations may need to be updated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription factor BTF3 homolog 4 (BTF3L4).